Proxy Votes Now

Home › Funds › Vanguard › Vanguard Health Care Index Fund

Vanguard Health Care Index Fund (VHT) proxy voting record 2025-2026

Fund family: Vanguard · Filed by VANGUARD WORLD FUND (CIK 52848) · SEC series S000004450

Share classes and tickers: VHT (C000012223), VHCIX (C000012222)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 4,370 with, 1,305 against, 40 abstentions (not counted as with management); 12 items carried no recommendation; 682 split votes are in neither count. Shareholder proposals: 2 FOR, 36 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Vanguard as a whole

The same two figures as Vanguard’s manager page (1,379,791 ballot items across 136 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsVanguardItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)91.8%5,58094.5%1,082,514
Backed environmental and social shareholder proposals at US companiesn/a90.9%6,718

Where this fund voted differently from most Vanguard funds

Each ballot item this fund voted is set against the votes of the other Vanguard funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Vanguard funds on 5 items (0.1% of the 4,552 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Vanguard fundsMgmtResult
Pliant Therapeutics, Inc.2026-06-11To approve, by non-binding advisory vote, the resolution approving Named Executive Officer compensation.AgainstFOR — 4 of 5 Vanguard fundsAgainstApproved, 51.2% support
Merck & Co., Inc.2026-05-26Election of Directors: Patrick F. RussoForAGAINST — 14 of 25 Vanguard fundsFor—
GoodRx Holdings, Inc.2026-06-16Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.AgainstFOR — 7 of 11 Vanguard fundsAgainstPassed (calculated), 99.0% support
Hologic, Inc.2026-02-05A proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to the named executive officers of the Company in connection with the transactions contemplated by the merger agreement, including consummation of the merger.AgainstFOR — 12 of 22 Vanguard fundsAgainst—
Quantum-Si Incorporated2026-05-15To approve, by a non-binding, advisory vote, the compensation of our named executive officers, as disclosed in this proxy statementAgainstFOR — 5 of 9 Vanguard fundsAgainst—

Download all 5 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 98.4% of this fund’s 5,715 such votes could be given a sector; the other 94 (1.6%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care5,0081,14422.8%
Industrials2938328.3%
Technology1482214.9%
Consumer Discretionary1282922.7%
Consumer Staples361541.7%
Finance800.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections5,0831,184
Audit-related47736
Say-on-Pay4520
Compensation23637
Corporate Governance10427
Capital Structure538
Extraordinary Transactions313
Shareholder Rights and Defenses161
Other Social Issues55
Environment or Climate33

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Eli Lilly and CompanyMay 4, 2026$6.9B146
Johnson & JohnsonApril 23, 2026$4.0B2713
AbbVie Inc.May 8, 2026$3.1B135
UnitedHealth Group IncorporatedJune 1, 2026$2.2B309
Merck & Co., Inc.May 26, 2026$2.1B3216
Thermo Fisher Scientific Inc.May 20, 2026$1.6B2411
Amgen Inc.May 19, 2026$1.5B3913
Gilead Sciences, Inc.April 30, 2026$1.2B3212

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalAgainstFor
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
April 23, 2026Johnson & JohnsonIndependent Board Chair Shareholder proposalAgainstFor
May 8, 2026AbbVie Inc.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalAgainstFor
June 1, 2026UnitedHealth Group IncorporatedIf properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 23, 2026Pfizer Inc.Adopt an Independent Chair Policy Shareholder proposalAgainstFor
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalAgainstFor

Contested meetings

Meetings with a proxy contest or competing nominees (3 in 2025-2026), and how the fund voted the items on its ballot.

Search this fund’s votes by company

6,461 ballot items at 428 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Vanguard Health Care Index Fund (VHT) voted at 428 shareholder meetings of 407 companies, on 6,461 ballot items in all. Where management made a recommendation, the fund followed it on 76.5% of the items and voted against it 1,305 times. Its most frequent area of disagreement was director elections (1,184 of its votes against management). It voted on 51 shareholder proposals. It voted FOR the board's own proposals less often than Vanguard's funds as a whole (91.8% against 94.5%). It voted differently from most Vanguard funds on 5 items. 3 of its meetings were contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Vanguard’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.